This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Ophthalmological Disorders, Other  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic

Daniel Calladine, BMBS, BMedSci; Rosalind J. Harrison, FRCOphth

Arch Ophthalmol. 2007;125(10):1427-1428.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Latanoprost is a 17 phenyl–substituted analogue of prostaglandin F₂ (PGF₂), which decreases intraocular pressure by increasing uveoscleral outflow. Since its introduction as a topical eye medication, several authors have reported adverse effects, like subtle hyperpigmentation of periocular skin and eyelid-margin hyperemia.¹ Herein, we present a case of a patient using latanoprost who developed severe darkening in a facial skin graft.

Report of a Case

A 68-year-old woman was diagnosed with primary open-angle glaucoma in September 2002. Topical latanoprost was commenced in both eyes, with a good control of intraocular pressure. In April 2005, a malignant melanoma was surgically excised from the left side of the patient's face and skin was grafted to this area from her neck behind the ear. Histology confirmed a low-risk, superficial, spreading malignant melanoma in situ, which was excised with adequate margins. In September 2005, severe darkening of the skin graft . . . [Full Text of this Article]

Comment

AUTHOR INFORMATION